High-Yield Expression of M2e Peptide of Avian Influenza Virus H5N1 in Transgenic Duckweed Plants

Molecular Biotechnology

Volumn 57, Issue 7, 2015, Pages 653-661

  Firsov, Aleksey ^a   Tarasenko, Irina ^a   Mitiouchkina, Tatiana ^a   Ismailova, Natalya ^a   Shaloiko, Lyubov ^a   Vainstein, Alexander ^b   Dolgov, Sergey ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Avian influenza; Duckweed; Peptide M2e; Plant based vaccine; Recombinant protein; Transgenic plant; Glucuronidase

Indexed keywords

ANTIGENS; CLONING; GENETICALLY MODIFIED PLANTS; PEPTIDES; PROTEINS; RECOMBINANT PROTEINS; VACCINES; VIRUSES;

AVIAN INFLUENZA; AVIAN INFLUENZA VIRUS; DUCKWEED; EXTRACELLULAR DOMAINS; GLUCURONIDASE; TOTAL SOLUBLE PROTEIN; TRANSGENIC PLANTS; VACCINE DEVELOPMENT;

PLANTS (BOTANY);

AVIAN INFLUENZA VACCINE; BETA GLUCURONIDASE; BETA GLUCURONIDASE ANTIBODY; M2E ANTIBODY; PROTEIN M2; PROTEIN M2E; UNCLASSIFIED DRUG; INFLUENZA VACCINE; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; RECOMBINANT PROTEIN;

AMINO TERMINAL SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; AVIAN INFLUENZA VIRUS; DNA SEQUENCE; INFLUENZA VIRUS A H5N1; LEMNA; MOLECULAR CLONING; NONHUMAN; PLASMID; PROTEIN EXPRESSION; TRANSGENIC PLANT; VIRUS STRAIN; ANIMAL; BIOSYNTHESIS; BIRD; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); INFLUENZA IN BIRDS; INFLUENZA, HUMAN; PATHOGENICITY; PLANT CELL; VIROLOGY;

AVES; AVIAN INFLUENZA VIRUS; LEMNA;

ANIMALS; BIRDS; GLUCURONIDASE; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PLANT CELLS; RECOMBINANT PROTEINS; VIRAL MATRIX PROTEINS;

EID: 84930871878     PISSN: 10736085     EISSN: 15590305     Source Type: Journal    
DOI: 10.1007/s12033-015-9855-4     Document Type: Article

References (37)

1. Chen, Q. (2011). Expression and manufacture of pharmaceutical proteins in genetically engineered horticultural plants. In B. Mou & R. Scorza (Eds.), Transgenic horticultural crops: Challenges and opportunities-essays by experts (pp. 83–124). Boca Raton, FL: Taylor & Francis.
2. Guan, Z. H., Guo, B., Huo, Y.-L., Guan, Z.-P., Dai, J.-K., & Wei, Y.-H. (2013). Recent advances and safety issues of transgenic plant-derived vaccines. Applied Microbiology and Biotechnology,97(7), 2817–2840.
3. Phan, H. T., Floss, D. M., & Conrad, U. (2013). Veterinary vaccines from transgenic plants: Highlights of two decades of research and a promising example. Current Pharmaceutical Design,19(31), 5601–5611.
4. Drake, P. M. W., & Thangaraj, H. (2010). Molecular farming, patents and access to medicines. Expert Review of Vaccines,9(8), 811–819.
5. Fischer, R., Schillberg, S., Hellwig, S., Twyman, R. M., & Drossard, J. (2012). GMP issues for recombinant plant-derived pharmaceutical proteins. Biotechnology Advances,30(2), 434–439.
6. Yusibov, V., Streatfield, S. J., & Kushnir, N. (2011). Clinical development of plant-produced recombinant pharmaceuticals. Human Vaccines,7(3), 1–9.
7. Kirk, D. D., McIntosh, K., Walmsley, A. M., & Peterson, R. K. D. (2005). Risk analysis for plant-made vaccines. Transgenic Research,14, 449–462.
8. Franconi, R., Demurtas, O. C., & Massa, S. (2010). Plant-derived vaccines and other therapeutics produced in contained systems. Expert Review of Vaccines,9(8), 877–892.
9. Gasdaska, J. R., Spencer, D., & Dickey, L. (2003). Advantages of therapeutic protein production in the aquatic plant Lemna. Bioprocessing Journal,2, 50–56.
10. Everett, K. M., Dickey, L., Parsons, J., Loranger, R., & Wingate, V. (2012). Development of a plant-made pharmaceutical production platform. BioProcess International,10(1), 16–25.
11. Sun, Y., Cheng, J. J., Himmel, M. E., Skory, C. D., Adney, W. S., Thomas, S. R., et al. (2007). Expression and characterization of Acidothermus cellulolyticus E1 endoglucanase in transgenic duckweed Lemna minor 8627. Bioresource Technology,98, 2866–2872.
12. Cox, K. M., Sterling, J. D., & Regan, J. T. (2006). Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nature Biotechnology,24(12), 1591–1597.
13. Ko, S.-M., Sun, H.-J., Oh, M. J., Song, I.-J., Kim, M.-J., Sin, H.-S., et al. (2011). Expression of the protective antigen for PEDV in transgenic duckweed Lemna minor. Horticulture Environment Biotechnology,52(5), 511–515.
14. Subbarao, K., & Matsuoka, Y. (2013). The prospects and challenges of universal vaccines for influenza. Trends in Microbiology,21(7), 350–358.
15. Pica, N., & Palese, P. (2013). Toward a universal influenza virus vaccine: Prospects and challenges. Annual Review of Medicine,64, 189–202.
16. Knipe, D. M., Samuel, C. E., & Palese, P. (2001). Virus-host cell interactions, Chapter 7. In D. M. Knipe, P. M. Howley, et al. (Eds.), Fields virology (4th ed., pp. 133–170). Philadelphia, PA: Lippincott, Williams and Wilkins.
17. Fiers, W., De Filette, M., Birkett, A., Neirynck, S., & Min Jou, W. (2004). A “universal” human influenza A vaccine. Virus Research,103, 173–176.
18. Reperant, L. A., Rimmelzwaan, G. F., & Osterhaus, A. D. (2014). Advances in influenza vaccination. F1000Prime Reports,6, 47.
19. Marcelin, G., Sandbulte, M. R., & Webb, R. J. (2012). Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Reviews in Medical Virology,22(4), 267–279.
20. Tumpey, T. M., Basler, C. F., Aguilar, P. V., Zeng, H., Solórzano, A., Swayne, D. E., et al. (2005). Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science,310(5745), 77–80.
21. Nemchinov, L. G., & Natilla, A. (2007). Transient expression of the ectodomain of matrix protein 2 (M2e) of avian influenza A virus in plants. Protein Expression and Purification,56, 153–159.
22. Denis, J., Acosta-Ramirez, E., Zhao, Y., Hamelin, M.-E., Koukavica, I., Baz, M., et al. (2008). Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine,26, 3395–3403.
23. Meshcheryakova, Y. A., Eldarov, M. A., Migunov, A. I., Stepanova, L. A., Repko, I. A., Kiselev, C. I., et al. (2009). Cowpea mosaic virus chimeric particles bearing the ectodomain of matrix protein 2 (M2E) of the influenza A virus: Production and characterization. Molecular Biology,43(4), 685–694.
24. Tyulkina, L. G., Skurat, E. V., Frolova, O. Y., Komarova, T. V., Karger, E. M., & Atabekov, I. G. (2011). New viral vector for superproduction of epitopes of vaccine proteins in plants. Acta Naturae,3(11), 73–82.
25. Streatfield, S. J. (2007). Approaches to achieve high-level heterologous protein production in plants. Plant Biotechnology Journal,5, 2–15.
26. Jefferson, R. A., Kavanagh’, T. A., & Bevan, M. W. (1987). GUS fusions: β-glucuronidase as a sensitive and versatile gene fusion marker in higher plants. EMBO Journal,6(13), 3901–3907.
27. Floss, D. M., Falkenburg, D., & Conrad, U. (2007). Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants: An overview. Transgenic Research,16, 315–332.
28. Murashige, T., & Skoog, F. (1962). A revised medium for rapid growth and bio-assays with tobacco tissue cultures. Physiologia Plantarum,15(3), 473–497.
29. Dellaporta, S. L., Wood, J., & Hicks, J. B. (1983). A plant DNA minipreparation version II. Plant Molecular Biology Reporter,1, 19–21.
30. Richter, L. J., Thanavala, Y., Arntzen, C. J., & Mason, H. S. (2000). Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nature Biotechnology,18, 1167–1171.
31. Sharma, A. K., & Sharma, M. K. (2009). Plants as bioreactors: Recent developments and emerging opportunities. Biotechnology Advances,27, 811–832.
32. Yamamoto, Y. T., Rajbhandari, N., Lin, X., Bergmann, B. A., Nishimura, Y., & Stomp, A.-M. (2001). Genetic transformation of duckweed Lemna gibba and Lemna minor. In Vitro Cellular & Developmental Biology-Plant,37, 349–353.
33. Li, J., Jain, M., Vunsh, R., Vishnevetsky, J., Hanania, U., Flaishman, M., et al. (2004). Callus induction and regeneration in Spirodela and Lemna. Plant Cell Reports,22, 457–464.
34. Chhabra, G., Chaudhary, D., Sainger, M., & Jaiwal, P. K. (2011). Genetic transformation of Indian isolate of Lemna minor mediated by Agrobacterium tumefaciens and recovery of transgenic plants. Physiology and Molecular Biology of Plants,17(2), 129–136.
35. Gil, F., Brun, A., Wigdorovitz, A., Catalá, R., Martínez-Torrecuadrada, J. L., Casal, I., et al. (2001). High-yield expression of a viral peptide vaccine in transgenic plants. FEBS Letters,488, 13–17.
36. Dus Santos, M. J., Wigdorovitz, A., Trono, K., Ríos, R. D., Franzone, P. M., Gil, F., et al. (2002). A novel methodology to develop a foot and mouth disease virus (FMDV) peptide-based vaccine in transgenic plants. Vaccine,20, 1141–1147.
37. Ravin, N. V., Kotlyarov, R. Y., Mardanova, E. S., Kuprianov, V. V., Migunov, A. I., Stepanova, L. A., et al. (2012). Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein. Biochemistry (Moscow),77(1), 33–40.